Insmed Incorporated (INSM) Q1 2025 10-Q Quarterly Report
Insmed Incorporated (INSM) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 8, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Insmed Incorporated Q1 2025 10-Q Analysis
Risk Factors
- • No new or updated risk factors disclosed this quarter compared to 10-K filing
- • Continued regulatory risk from FDA approval delays impacting product launch timing and revenue realization
Insmed Incorporated Q1 2025 Quarterly FinancialsXBRL
Revenue
$93M
▲ +22.9% YoY
Net Income
-$257M
▼ -63.3% YoY
Net Margin
-276.4%
▼ -6835bp YoY
Source: XBRL data from Insmed Incorporated Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Insmed Incorporated Quarterly Reports
Get deeper insights on Insmed Incorporated
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.